Back to Supplement Finder

Ovagen Peptide X 20mg

Sold by FMI Health

INR 9,814.00

View at FMI Health
Store
fmihealth.com
Brand
Biolongevity Labs
Product type
Peptides
Collected
2026-11-20

From the retailer

Retailer description retrieved 2026-11-20. Claims are the retailer’s, not independently verified.

Description-- Ovagen is a research‑grade tripeptide bioregulator developed within the Khavinson peptide program. It demonstrates specific affinity for hepatic tissue and is designed for in vitro applications investigating liver and gastrointestinal tract function. Supplied as a high‑purity lyophilized peptide complex, Ovagen provides laboratories with consistent, reliable material for cellular and tissue research.

 

Mechanistic Claims

  • Liver Function Support: Targets hepatic tissue pathways in research models.
  • Immune & GI Regulation: Explored for roles in gastrointestinal tract and immune system modulation.
  • Cellular Research Utility: Provides a simplified peptide model for studying bioregulatory mechanisms.
  • Anti‑Aging Potential: Investigated for effects on cellular function and tissue resilience.
  • Thymus & Immune Links: As part of Khavinson’s peptide library, contributes to broader immune regulation studies.

 

Research Applications

  • Liver function and hepatocyte biology studies
  • Gastrointestinal tract regulation models
  • Immune system and peptide bioregulator investigations
  • Cellular aging and tissue resilience research
  • Exploratory anti‑aging and regenerative medicine studies

 

Ovagen Research Insights

  • Synthetic tripeptide bioregulator with hepatic tissue affinity.
  • Developed for in vitro research only; not intended for therapeutic use.
  • Manufactured in USA facilities under rigorous quality control standards.
  • Each batch undergoes independent third‑party purity verification for reliable outcomes.
  • Supplied in lyophilized, filler‑free form to preserve integrity and extend shelf life.


Ovagen Research

 

HIV-1 Protease Inhibition Research

The most substantive research on the Glu-Asp-Leu tripeptide comes from HIV-1 protease inhibition studies where EDL functions as a competitive inhibitor derived from the viral transframe region (TFR). The tripeptide represents one of the smallest and most potent analogues derived from the transframe octapeptide (TFP) Phe-Leu-Arg-Glu-Asp-Leu-Ala-Phe, which naturally occurs at the N-terminus of the HIV-1 transframe region[1].

Kinetic analysis demonstrates that Glu-Asp-Leu exhibits competitive inhibition of mature HIV-1 protease with a Ki value of approximately 50 μM. This inhibitory potency is remarkable considering the tripeptide’s simple structure compared to conventional HIV protease inhibitors. The closely related tripeptide Glu-Asp-Phe shows even greater potency with a Ki value of approximately 20 μM[1].

 

References

  1. J. M. Louis, F. Dyda, N. T. Nashed, A. R. Kimmel, and D. R. Davies, “Hydrophilic Peptides Derived from the Transframe Region of Gag-Pol Inhibit the HIV-1 Protease,” American Chemical Society (ACS), Feb. 1998. doi: 10.1021/bi972059x.


Label--Peptide Information

Property Value
Peptide Sequence H-Glu-Asp-Leu-OH
Molecular Formula C₁₅H₂₅N₃O₈
Molecular Weight 375.37 g/mol
PubChem CID 444128

 

Dosage--This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY.